Jennifer A. Fifita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer A. Fifita has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Ian P. Blair
Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia
28 shared publications - Emily P. McCann
Macquarie University Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia
14 shared publications - Kelly Louise Williams
Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
13 shared publications Garth A. Nicholson
Macquarie University Centre for Motor Neuron Disease Research, Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia; Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; Molecular Medicine Laboratory, Concord Hospital, Sydney, New South Wales, Australia
11 shared publications- Dominic Brock Rowe
MND Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia
8 shared publications - Shu Yang
Macquarie University
8 shared publications
Latest Publications
- 4 November 2022
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 23 (sup1) , 40-56
Theme 02 - Genetics and Genomics
Hereditary spastic paraplegia (HSP) is a heterogeneous group of genetic neurodegenerative disorders characterized by progressive weakness and spasticity of lower limbs. SPG15 is a rare form of autosomal recessive HSP due to mutations in ZFYVE26 gene, which encodes for spastizin, involved in autophagy and endocytosis ( 1 ). Here we describe the case of a 56 years old man who presented to our clinic in November 2020 referring a progressive motor clumsiness of both legs and walking instability during the last five years. No motor impairment at upper limb, no bulbar nor respiratory symptoms. These symptoms had a progressive evolution. In anamnesis only high blood pressure. No familiar history of neurodegenerative diseases. Neurological examination showed a spastic gait, a light hypotrophy and hyposthenia of the left leg, brisk reflexes at lower limb, no Hoffmann nor Babinski signs, no urinary nor intestinal problems. He underwent: blood examination (resulted normal, no HIV, HTLV infections), electroneurography/electromyography study (signs of chronic neurogenic muscle damage at lower limbs), brain MRI (normal), cervical MRI (normal medulla, small discal hernias without radicular or medulla compression), neuropsychological tests (executive and visuo-spatial impairments). On the basis of these examinations, we suspected a primary form of upper motor neuron disease. Therefore, we prescribed rehabilitation (with partial improvement of gait disturbances) and we executed a genetic examination in the suspect of a rare form of HSP. We observed a homozygous mutation in ZFYVE26 gene, which is the cause of a rare form of HSP (the SPG15). In detail, the mutation we found (c.195-1G>A) is a novel deletion in ZFYVE26 gene, never described in literature. This is a mutation in a splicing site and an in-silico evaluation demonstrated its pathogenic role. The clinical features of our patient are superimposable to other cases of SPG15. Background: Nicotinamide adenine dinucleotide (NAD+) is a central component for cell metabolism, and a vital factor for function of various groups of enzymes involved in pathways such as DNA repair, inflammation, genomic stability and stress resistance. NAD + is synthesised through three pathways; the Kynurenine, Preiss-Handler and salvage pathways. Conversely, NAD + is consumed to its reduced form nicotinamide adenine dinucleotide (NADH) via poly (ADP-ribose) polymerases (PARPs), sirtuins (SIRTs), ADP-ribosyl cyclases (CD38/CD157), and Sterile alpha and TIR motif containing 1 (SARM1). Reduced NAD + levels caused by impairment of enzymes involved in NAD + biosynthesis or up-regulation of enzymes that consume NAD + have been associated with aging and several neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). While gene mutations are known to cause ALS, the genetics of ALS is highly complex, whereby only approximately 60–70% of familial and 10% of sporadic ALS cases have a known genetic cause. In additional to causal gene mutations, multiple gene variants may also act synergistically, with or without environmental influence, to cause or confer risk to the development of ALS. Objectives: We aimed to determine the genetic contribution of 36 genes involved in NAD + biosynthesis (focusing on Preiss handler and Salvage pathway, Kynurenine pathways), and NAD + consumption (PARPs, SIRTs, CD38/CD157, SARM1) by identification of novel gene variants and gene burden in a large cohort of Australian sporadic ALS cases. Methods: Whole-genome sequencing data from 609 Australian sporadic ALS cases was screened through the 36 genes. Novel variants absent in public control databases, and rare protein-altering variants (for gene burden analysis) were identified. For burden analysis, variants in genes involved in NAD + synthesis and each consumption pathway were grouped, and compared to two independent control databases. Results: Forty-two novel variants identified in 26/36 genes were identified. Burden analysis of rare variants performed on genes in combined Preiss-handler and Salvage pathway (NAD + synthesis), and genes belonging to the SIRT family (NAD + consumption) was statistically significant (p = 0.0014 and p = 0.006 respectively) when compared to Project MinE controls. Discussion: Some of these variants may represent ALS risk factors that disrupt NAD + biosynthesis or consumption, hence altering NAD + levels in ALS patients. Overall, our genetic findings suggest that rare genetic mutations in genes that alter NAD + levels may be associated with sporadic ALS in Australia. There is potential for therapeutic drugs that boost NAD + levels in ALS patients, and future studies can assess the specific pathogenic role of novel variants identified in patients to improve our understanding underlying the mechanisms of disease. SINE-VNTR-Alu (SVA) retrotransposons are transposable elements which are capable of propagating throughout the genome and hence represent a source of genetic variation. We previously demonstrated that presence or absence of a human-specific SVA, termed SVA_67, correlated with both isoform- and tissue-specific expression of multiple genes at the MAPT locus, a locus associated with several neurodegenerative diseases including frontotemporal dementia and other tauopathies. A problem in defining regulatory associations is that this region is contained within a large genomic inversion termed H1/H2. We have identified that SVA _67 tags the H1 inversion and we are extending our analysis to distinguish the SVA specific regulation from that associated with the inversion. In the current study we show that SVA_67 is not only a retrotransposon insertion polymorphism (RIP), but also variable in the size of its variable number tandem repeat (VNTR) domain. Four different alleles of the SVA_67 VNTR were identified which demonstrated differential properties of a regulatory domain in a reporter gene assay. We expanded these findings by...
- 4 November 2022
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 23 (sup1) , 40-56
Theme 02 - Genetics and Genomics
Hereditary spastic paraplegia (HSP) is a heterogeneous group of genetic neurodegenerative disorders characterized by progressive weakness and spasticity of lower limbs. SPG15 is a rare form of autosomal recessive HSP due to mutations in ZFYVE26 gene, which encodes for spastizin, involved in autophagy and endocytosis ( 1 ). Here we describe the case of a 56 years old man who presented to our clinic in November 2020 referring a progressive motor clumsiness of both legs and walking instability during the last five years. No motor impairment at upper limb, no bulbar nor respiratory symptoms. These symptoms had a progressive evolution. In anamnesis only high blood pressure. No familiar history of neurodegenerative diseases. Neurological examination showed a spastic gait, a light hypotrophy and hyposthenia of the left leg, brisk reflexes at lower limb, no Hoffmann nor Babinski signs, no urinary nor intestinal problems. He underwent: blood examination (resulted normal, no HIV, HTLV infections), electroneurography/electromyography study (signs of chronic neurogenic muscle damage at lower limbs), brain MRI (normal), cervical MRI (normal medulla, small discal hernias without radicular or medulla compression), neuropsychological tests (executive and visuo-spatial impairments). On the basis of these examinations, we suspected a primary form of upper motor neuron disease. Therefore, we prescribed rehabilitation (with partial improvement of gait disturbances) and we executed a genetic examination in the suspect of a rare form of HSP. We observed a homozygous mutation in ZFYVE26 gene, which is the cause of a rare form of HSP (the SPG15). In detail, the mutation we found (c.195-1G>A) is a novel deletion in ZFYVE26 gene, never described in literature. This is a mutation in a splicing site and an in-silico evaluation demonstrated its pathogenic role. The clinical features of our patient are superimposable to other cases of SPG15. Background: Nicotinamide adenine dinucleotide (NAD+) is a central component for cell metabolism, and a vital factor for function of various groups of enzymes involved in pathways such as DNA repair, inflammation, genomic stability and stress resistance. NAD + is synthesised through three pathways; the Kynurenine, Preiss-Handler and salvage pathways. Conversely, NAD + is consumed to its reduced form nicotinamide adenine dinucleotide (NADH) via poly (ADP-ribose) polymerases (PARPs), sirtuins (SIRTs), ADP-ribosyl cyclases (CD38/CD157), and Sterile alpha and TIR motif containing 1 (SARM1). Reduced NAD + levels caused by impairment of enzymes involved in NAD + biosynthesis or up-regulation of enzymes that consume NAD + have been associated with aging and several neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). While gene mutations are known to cause ALS, the genetics of ALS is highly complex, whereby only approximately 60–70% of familial and 10% of sporadic ALS cases have a known genetic cause. In additional to causal gene mutations, multiple gene variants may also act synergistically, with or without environmental influence, to cause or confer risk to the development of ALS. Objectives: We aimed to determine the genetic contribution of 36 genes involved in NAD + biosynthesis (focusing on Preiss handler and Salvage pathway, Kynurenine pathways), and NAD + consumption (PARPs, SIRTs, CD38/CD157, SARM1) by identification of novel gene variants and gene burden in a large cohort of Australian sporadic ALS cases. Methods: Whole-genome sequencing data from 609 Australian sporadic ALS cases was screened through the 36 genes. Novel variants absent in public control databases, and rare protein-altering variants (for gene burden analysis) were identified. For burden analysis, variants in genes involved in NAD + synthesis and each consumption pathway were grouped, and compared to two independent control databases. Results: Forty-two novel variants identified in 26/36 genes were identified. Burden analysis of rare variants performed on genes in combined Preiss-handler and Salvage pathway (NAD + synthesis), and genes belonging to the SIRT family (NAD + consumption) was statistically significant (p = 0.0014 and p = 0.006 respectively) when compared to Project MinE controls. Discussion: Some of these variants may represent ALS risk factors that disrupt NAD + biosynthesis or consumption, hence altering NAD + levels in ALS patients. Overall, our genetic findings suggest that rare genetic mutations in genes that alter NAD + levels may be associated with sporadic ALS in Australia. There is potential for therapeutic drugs that boost NAD + levels in ALS patients, and future studies can assess the specific pathogenic role of novel variants identified in patients to improve our understanding underlying the mechanisms of disease. SINE-VNTR-Alu (SVA) retrotransposons are transposable elements which are capable of propagating throughout the genome and hence represent a source of genetic variation. We previously demonstrated that presence or absence of a human-specific SVA, termed SVA_67, correlated with both isoform- and tissue-specific expression of multiple genes at the MAPT locus, a locus associated with several neurodegenerative diseases including frontotemporal dementia and other tauopathies. A problem in defining regulatory associations is that this region is contained within a large genomic inversion termed H1/H2. We have identified that SVA _67 tags the H1 inversion and we are extending our analysis to distinguish the SVA specific regulation from that associated with the inversion. In the current study we show that SVA_67 is not only a retrotransposon insertion polymorphism (RIP), but also variable in the size of its variable number tandem repeat (VNTR) domain. Four different alleles of the SVA_67 VNTR were identified which demonstrated differential properties of a regulatory domain in a reporter gene assay. We expanded these findings by...
- 1 May 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 101, 297.e9-297.e11
Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis
- 1 May 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 101, 297.e9-297.e11
Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis
- Open Access
SFPQ intron retention, reduced expression and aggregate formation in central nervous system tissue are pathological features of amyotrophic lateral sclerosis
Background: Splicing factor proline and glutamine rich (SFPQ, also known as polypyrimidine tract-binding protein-associated-splicing factor, PSF) is a RNA-DNA binding protein with roles in key cellular pathways such as DNA transcription and repair, RNA processing and paraspeckle formation. Dysregulation of SFPQ is emerging as a common pathological feature of multiple neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Increased retention of SFPQ intron nine and nuclear loss of the protein have been linked to multiple genetic subtypes of ALS. Consequently, SFPQ dysregulation has been hypothesised to be a common pathological feature of this highly heterogeneous disease. Methods: This study provides a comprehensive assessment of SFPQ pathology in large ALS patient cohorts. SFPQ gene expression and intron nine retention were examined in multiple neuroanatomical regions and blood from ALS patients and control individuals using RNA sequencing (RNA-Seq) and quantitative PCR (RT-qPCR). SFPQ protein levels were assessed by immunoblotting of patient and control motor cortex and SFPQ expression pattern was examined by immunofluorescent staining of patient and control spinal cord sections. Finally, whole-genome sequencing data from a large cohort of sporadic ALS patients was analysed for genetic variation in SFPQ . Results: SFPQ intron nine retention was significantly increased in ALS patient motor cortex. Total SFPQ mRNA expression was significantly downregulated in ALS patient motor cortex but not ALS patient blood, indicating tissue specific SFPQ dysregulation. At the protein level, nuclear expression of SFPQ in both control and patient spinal motor neurons was highly variable and nuclear depletion of SFPQ was not a consistent feature in our ALS cohort. However, we did observe SFPQ-positive cytoplasmic ubiquitinated protein aggregates in ALS spinal motor neurons. In addition, our genetic screen of ALS patients identified two novel, and two rare sequence variants in SFPQ not previously reported in ALS. Conclusions: This study shows that dysregulation of SFPQ is a feature of ALS patient central nervous system tissue. These findings confirm SFPQ pathology as a feature of ALS and indicate that investigations into the functional consequences of this pathology will provide insight into the biology of ALS.
Open AccessSFPQ intron retention, reduced expression and aggregate formation in central nervous system tissue are pathological features of amyotrophic lateral sclerosis
Background: Splicing factor proline and glutamine rich (SFPQ, also known as polypyrimidine tract-binding protein-associated-splicing factor, PSF) is a RNA-DNA binding protein with roles in key cellular pathways such as DNA transcription and repair, RNA processing and paraspeckle formation. Dysregulation of SFPQ is emerging as a common pathological feature of multiple neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). Increased retention of SFPQ intron nine and nuclear loss of the protein have been linked to multiple genetic subtypes of ALS. Consequently, SFPQ dysregulation has been hypothesised to be a common pathological feature of this highly heterogeneous disease. Methods: This study provides a comprehensive assessment of SFPQ pathology in large ALS patient cohorts. SFPQ gene expression and intron nine retention were examined in multiple neuroanatomical regions and blood from ALS patients and control individuals using RNA sequencing (RNA-Seq) and quantitative PCR (RT-qPCR). SFPQ protein levels were assessed by immunoblotting of patient and control motor cortex and SFPQ expression pattern was examined by immunofluorescent staining of patient and control spinal cord sections. Finally, whole-genome sequencing data from a large cohort of sporadic ALS patients was analysed for genetic variation in SFPQ . Results: SFPQ intron nine retention was significantly increased in ALS patient motor cortex. Total SFPQ mRNA expression was significantly downregulated in ALS patient motor cortex but not ALS patient blood, indicating tissue specific SFPQ dysregulation. At the protein level, nuclear expression of SFPQ in both control and patient spinal motor neurons was highly variable and nuclear depletion of SFPQ was not a consistent feature in our ALS cohort. However, we did observe SFPQ-positive cytoplasmic ubiquitinated protein aggregates in ALS spinal motor neurons. In addition, our genetic screen of ALS patients identified two novel, and two rare sequence variants in SFPQ not previously reported in ALS. Conclusions: This study shows that dysregulation of SFPQ is a feature of ALS patient central nervous system tissue. These findings confirm SFPQ pathology as a feature of ALS and indicate that investigations into the functional consequences of this pathology will provide insight into the biology of ALS.
- Open Access
A Simple Differentiation Protocol for Generation of Induced Pluripotent Stem Cell-Derived Basal Forebrain-Like Cholinergic Neurons for Alzheimer’s Disease and Frontotemporal Dementia Disease Modeling
The study of neurodegenerative diseases using pluripotent stem cells requires new methods to assess neurodevelopment and neurodegeneration of specific neuronal subtypes. The cholinergic system, characterized by its use of the neurotransmitter acetylcholine, is one of the first to degenerate in Alzheimer’s disease and is also affected in frontotemporal dementia. We developed a differentiation protocol to generate basal forebrain-like cholinergic neurons (BFCNs) from induced pluripotent stem cells (iPSCs) aided by the use of small molecule inhibitors and growth factors. Ten iPSC lines were successfully differentiated into BFCNs using this protocol. The neuronal cultures were characterised through RNA and protein expression, and functional analysis of neurons was confirmed by whole-cell patch clamp. We have developed a reliable protocol using only small molecule inhibitors and growth factors, while avoiding transfection or cell sorting methods, to achieve a BFCN culture that expresses the characteristic markers of cholinergic neurons.
Open AccessA Simple Differentiation Protocol for Generation of Induced Pluripotent Stem Cell-Derived Basal Forebrain-Like Cholinergic Neurons for Alzheimer’s Disease and Frontotemporal Dementia Disease Modeling
The study of neurodegenerative diseases using pluripotent stem cells requires new methods to assess neurodevelopment and neurodegeneration of specific neuronal subtypes. The cholinergic system, characterized by its use of the neurotransmitter acetylcholine, is one of the first to degenerate in Alzheimer’s disease and is also affected in frontotemporal dementia. We developed a differentiation protocol to generate basal forebrain-like cholinergic neurons (BFCNs) from induced pluripotent stem cells (iPSCs) aided by the use of small molecule inhibitors and growth factors. Ten iPSC lines were successfully differentiated into BFCNs using this protocol. The neuronal cultures were characterised through RNA and protein expression, and functional analysis of neurons was confirmed by whole-cell patch clamp. We have developed a reliable protocol using only small molecule inhibitors and growth factors, while avoiding transfection or cell sorting methods, to achieve a BFCN culture that expresses the characteristic markers of cholinergic neurons.
- 14 May 2020
- Published by BMJ in Journal of Medical Genetics
- Vol. 58 (2) , 87-95
Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with phenotypic and genetic heterogeneity. Approximately 10% of cases are familial, while remaining cases are classified as sporadic. To date, >30 genes and several hundred genetic variants have been implicated in ALS. Methods: Seven hundred and fifty-seven sporadic ALS cases were recruited from Australian neurology clinics. Detailed clinical data and whole genome sequencing (WGS) data were available from 567 and 616 cases, respectively, of which 426 cases had both datasets available. As part of a comprehensive genetic analysis, 853 genetic variants previously reported as ALS-linked mutations or disease-associated alleles were interrogated in sporadic ALS WGS data. Statistical analyses were performed to identify correlation between clinical variables, and between phenotype and the number of ALS-implicated variants carried by an individual. Relatedness between individuals carrying identical variants was assessed using identity-by-descent analysis. Results: Forty-three ALS-implicated variants from 18 genes, including C9orf72, ATXN2, TARDBP, SOD1, SQSTM1 and SETX, were identified in Australian sporadic ALS cases. One-third of cases carried at least one variant and 6.82% carried two or more variants, implicating a potential oligogenic or polygenic basis of ALS. Relatedness was detected between two sporadic ALS cases carrying a SOD1 p.I114T mutation, and among three cases carrying a SQSTM1 p.K238E mutation. Oligogenic/polygenic sporadic ALS cases showed earlier age of onset than those with no reported variant. Conclusion: We confirm phenotypic associations among ALS cases, and highlight the contribution of genetic variation to all forms of ALS.
- 14 May 2020
- Published by BMJ in Journal of Medical Genetics
- Vol. 58 (2) , 87-95
Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with phenotypic and genetic heterogeneity. Approximately 10% of cases are familial, while remaining cases are classified as sporadic. To date, >30 genes and several hundred genetic variants have been implicated in ALS. Methods: Seven hundred and fifty-seven sporadic ALS cases were recruited from Australian neurology clinics. Detailed clinical data and whole genome sequencing (WGS) data were available from 567 and 616 cases, respectively, of which 426 cases had both datasets available. As part of a comprehensive genetic analysis, 853 genetic variants previously reported as ALS-linked mutations or disease-associated alleles were interrogated in sporadic ALS WGS data. Statistical analyses were performed to identify correlation between clinical variables, and between phenotype and the number of ALS-implicated variants carried by an individual. Relatedness between individuals carrying identical variants was assessed using identity-by-descent analysis. Results: Forty-three ALS-implicated variants from 18 genes, including C9orf72, ATXN2, TARDBP, SOD1, SQSTM1 and SETX, were identified in Australian sporadic ALS cases. One-third of cases carried at least one variant and 6.82% carried two or more variants, implicating a potential oligogenic or polygenic basis of ALS. Relatedness was detected between two sporadic ALS cases carrying a SOD1 p.I114T mutation, and among three cases carrying a SQSTM1 p.K238E mutation. Oligogenic/polygenic sporadic ALS cases showed earlier age of onset than those with no reported variant. Conclusion: We confirm phenotypic associations among ALS cases, and highlight the contribution of genetic variation to all forms of ALS.
- Open Access
- 1 March 2020
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (3) , 783-799
CYLD is a causative gene for frontotemporal dementia – amyotrophic lateral sclerosis
Frontotemporal dementia and amyotrophic lateral sclerosis are clinically and pathologically overlapping disorders with shared genetic causes. We previously identified a disease locus on chromosome 16p12.1-q12.2 with genome-wide significant linkage in a large European Australian family with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosis and no mutation in known amyotrophic lateral sclerosis or dementia genes. Here we demonstrate the segregation of a novel missense variant in CYLD (c.2155A>G, p.M719V) within the linkage region as the genetic cause of disease in this family. Immunohistochemical analysis of brain tissue from two CYLD p.M719V mutation carriers showed widespread glial CYLD immunoreactivity. Primary mouse neurons transfected with CYLDM719V exhibited increased cytoplasmic localization of TDP-43 and shortened axons. CYLD encodes a lysine 63 deubiquitinase and CYLD cutaneous syndrome, a skin tumour disorder, is caused by mutations that lead to reduced deubiquitinase activity. In contrast with CYLD cutaneous syndrome-causative mutations, CYLDM719V exhibited significantly increased lysine 63 deubiquitinase activity relative to the wild-type enzyme (paired Wilcoxon signed-rank test P = 0.005). Overexpression of CYLDM719V in HEK293 cells led to more potent inhibition of the cell signalling molecule NF-κB and impairment of autophagosome fusion to lysosomes, a key process in autophagy. Although CYLD mutations appear to be rare, CYLD’s interaction with at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral sclerosis genes (TBK1, OPTN and SQSTM1) suggests that it may play a central role in the pathogenesis of these disorders. Mutations in several frontotemporal dementia and amyotrophic lateral sclerosis genes, including TBK1, OPTN and SQSTM1, result in a loss of autophagy function. We show here that increased CYLD activity also reduces autophagy function, highlighting the importance of autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.
- 1 March 2020
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (3) , 783-799
Open AccessCYLD is a causative gene for frontotemporal dementia – amyotrophic lateral sclerosis
Frontotemporal dementia and amyotrophic lateral sclerosis are clinically and pathologically overlapping disorders with shared genetic causes. We previously identified a disease locus on chromosome 16p12.1-q12.2 with genome-wide significant linkage in a large European Australian family with autosomal dominant inheritance of frontotemporal dementia and amyotrophic lateral sclerosis and no mutation in known amyotrophic lateral sclerosis or dementia genes. Here we demonstrate the segregation of a novel missense variant in CYLD (c.2155A>G, p.M719V) within the linkage region as the genetic cause of disease in this family. Immunohistochemical analysis of brain tissue from two CYLD p.M719V mutation carriers showed widespread glial CYLD immunoreactivity. Primary mouse neurons transfected with CYLDM719V exhibited increased cytoplasmic localization of TDP-43 and shortened axons. CYLD encodes a lysine 63 deubiquitinase and CYLD cutaneous syndrome, a skin tumour disorder, is caused by mutations that lead to reduced deubiquitinase activity. In contrast with CYLD cutaneous syndrome-causative mutations, CYLDM719V exhibited significantly increased lysine 63 deubiquitinase activity relative to the wild-type enzyme (paired Wilcoxon signed-rank test P = 0.005). Overexpression of CYLDM719V in HEK293 cells led to more potent inhibition of the cell signalling molecule NF-κB and impairment of autophagosome fusion to lysosomes, a key process in autophagy. Although CYLD mutations appear to be rare, CYLD’s interaction with at least three other proteins encoded by frontotemporal dementia and/or amyotrophic lateral sclerosis genes (TBK1, OPTN and SQSTM1) suggests that it may play a central role in the pathogenesis of these disorders. Mutations in several frontotemporal dementia and amyotrophic lateral sclerosis genes, including TBK1, OPTN and SQSTM1, result in a loss of autophagy function. We show here that increased CYLD activity also reduces autophagy function, highlighting the importance of autophagy regulation in the pathogenesis of frontotemporal dementia and amyotrophic lateral sclerosis.
- 5 November 2019
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 91 (2) , 162-171
Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice
Objective: Since the first report ofCHCHD10gene mutations in amyotrophiclateral sclerosis (ALS)/frontotemporaldementia (FTD) patients, genetic variation inCHCHD10has been inconsistently linked to disease. A pathological assessment of the CHCHD10 protein in patient neuronal tissue also remains to be reported. We sought to characterise the genetic and pathological contribution of CHCHD10 to ALS/FTD in Australia.Methods: Whole-exome and whole-genome sequencing data from 81 familial and 635 sporadic ALS, and 108 sporadic FTD cases, were assessed for genetic variation inCHCHD10. CHCHD10 protein expression was characterised by immunohistochemistry, immunofluorescence and western blotting in control, ALS and/or FTD postmortem tissues and further in a transgenic mouse model of TAR DNA-binding protein 43 (TDP-43) pathology.Results: No causal, novel or disease-associated variants inCHCHD10were identified in Australian ALS and/or FTD patients. In human brain and spinal cord tissues, CHCHD10 was specifically expressed in neurons. A significant decrease in CHCHD10 protein level was observed in ALS patient spinal cord and FTD patient frontal cortex. In a TDP-43 mouse model with a regulatable nuclear localisation signal (rNLS TDP-43 mouse), CHCHD10 protein levels were unaltered at disease onset and early in disease, but were significantly decreased in cortex in mid-stage disease.Conclusions: Genetic variation inCHCHD10is not a common cause of ALS/FTD in Australia. However, we showed that in humans, CHCHD10 may play a neuron-specific role and a loss of CHCHD10 function may be linked to ALS and/or FTD. Our data from the rNLS TDP-43 transgenic mice suggest that a decrease in CHCHD10 levels is a late event in aberrant TDP-43-induced ALS/FTD pathogenesis.
- 5 November 2019
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 91 (2) , 162-171
Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice
Objective: Since the first report ofCHCHD10gene mutations in amyotrophiclateral sclerosis (ALS)/frontotemporaldementia (FTD) patients, genetic variation inCHCHD10has been inconsistently linked to disease. A pathological assessment of the CHCHD10 protein in patient neuronal tissue also remains to be reported. We sought to characterise the genetic and pathological contribution of CHCHD10 to ALS/FTD in Australia.Methods: Whole-exome and whole-genome sequencing data from 81 familial and 635 sporadic ALS, and 108 sporadic FTD cases, were assessed for genetic variation inCHCHD10. CHCHD10 protein expression was characterised by immunohistochemistry, immunofluorescence and western blotting in control, ALS and/or FTD postmortem tissues and further in a transgenic mouse model of TAR DNA-binding protein 43 (TDP-43) pathology.Results: No causal, novel or disease-associated variants inCHCHD10were identified in Australian ALS and/or FTD patients. In human brain and spinal cord tissues, CHCHD10 was specifically expressed in neurons. A significant decrease in CHCHD10 protein level was observed in ALS patient spinal cord and FTD patient frontal cortex. In a TDP-43 mouse model with a regulatable nuclear localisation signal (rNLS TDP-43 mouse), CHCHD10 protein levels were unaltered at disease onset and early in disease, but were significantly decreased in cortex in mid-stage disease.Conclusions: Genetic variation inCHCHD10is not a common cause of ALS/FTD in Australia. However, we showed that in humans, CHCHD10 may play a neuron-specific role and a loss of CHCHD10 function may be linked to ALS and/or FTD. Our data from the rNLS TDP-43 transgenic mice suggest that a decrease in CHCHD10 levels is a late event in aberrant TDP-43-induced ALS/FTD pathogenesis.
- 23 March 2019
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (5-6) , 310-316
The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling
C9orf72 hexanucleotide repeat expansions are the most common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Genetic testing for C9orf72 expansions in patients with ALS and/or FTD and their relatives has become increasingly available since hexanucleotide repeat expansions were first reported in 2011. The repeat number is highly variable and the threshold at which repeat size leads to neurodegeneration remains unknown. We present the case of an ALS patient who underwent genetic testing through our Motor Neurone Disease Clinic. We highlight current limitations to analysing and interpreting C9orf72 expansion test results and describe how this resulted in discordant reports of pathogenicity between testing laboratories that confounded the genetic counselling process. We conclude that patients with ALS or FTD and their at-risk family members, need to be adequately counselled about the limitations of current knowledge to ensure they are making informed decisions about genetic testing for C9orf72. Greater collaboration between clinicians, testing laboratories and researchers is required to ensure risks to patients and their families are minimised.
- 23 March 2019
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 20 (5-6) , 310-316
The C9orf72 hexanucleotide repeat expansion presents a challenge for testing laboratories and genetic counseling
C9orf72 hexanucleotide repeat expansions are the most common known cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Genetic testing for C9orf72 expansions in patients with ALS and/or FTD and their relatives has become increasingly available since hexanucleotide repeat expansions were first reported in 2011. The repeat number is highly variable and the threshold at which repeat size leads to neurodegeneration remains unknown. We present the case of an ALS patient who underwent genetic testing through our Motor Neurone Disease Clinic. We highlight current limitations to analysing and interpreting C9orf72 expansion test results and describe how this resulted in discordant reports of pathogenicity between testing laboratories that confounded the genetic counselling process. We conclude that patients with ALS or FTD and their at-risk family members, need to be adequately counselled about the limitations of current knowledge to ensure they are making informed decisions about genetic testing for C9orf72. Greater collaboration between clinicians, testing laboratories and researchers is required to ensure risks to patients and their families are minimised.
- Open Access
- 27 October 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 28 (4) , 698
Expression of ALS/FTD-linked mutant CCNF in zebrafish leads to increased cell death in the spinal cord and an aberrant motor phenotype
Human Molecular Genetics, doi: 10.1093/hmg/ddx136.
- 27 October 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 28 (4) , 698
Open AccessExpression of ALS/FTD-linked mutant CCNF in zebrafish leads to increased cell death in the spinal cord and an aberrant motor phenotype
Human Molecular Genetics, doi: 10.1093/hmg/ddx136.
- 19 March 2018
- Published by Sciencematters in Matters (Zürich)
- Vol. 4 (3)
Constitutive overexpression of the ALS-linked gene CCNF fusions results in cytotoxicity to preclude generation of transgenic zebrafish models
The E3 ubiquitin ligase protein, cyclin F (encoded by CCNF) has a role in substrate recognition for protein degradation within the ubiquitin proteasomal system. Mutations in this gene have recently been linked to the neurodegenerative diseases amyotrophic lateral sclerosis and frontotemporal dementia. To investigate the role of CCNF dysfunction in neurodegenerative disease, we aimed to develop novel transgenic zebrafish models that constitutively overexpress CCNF fusion proteins. After several attempts at establishing these transgenic lines, with side-by-side successful controls, it became apparent that generation of constitutively overexpressing CCNF fusion transgenic lines was not feasible. This failure appears to be a result of toxicity associated with persistent overexpression of CCNF fusion proteins in the developing embryo that precludes germ-line transmission of the transgene. The observations from our study indicate that an additional screening stage of zebrafish embryos, and/or the use of a temporal inducible system/mechanism is warranted in studies that aim to develop transgenic models expressing potentially toxic proteins, to circumvent the issues produced by expression during early developmental stages.
- 19 March 2018
- Published by Sciencematters in Matters (Zürich)
- Vol. 4 (3)
Constitutive overexpression of the ALS-linked gene CCNF fusions results in cytotoxicity to preclude generation of transgenic zebrafish models
The E3 ubiquitin ligase protein, cyclin F (encoded by CCNF) has a role in substrate recognition for protein degradation within the ubiquitin proteasomal system. Mutations in this gene have recently been linked to the neurodegenerative diseases amyotrophic lateral sclerosis and frontotemporal dementia. To investigate the role of CCNF dysfunction in neurodegenerative disease, we aimed to develop novel transgenic zebrafish models that constitutively overexpress CCNF fusion proteins. After several attempts at establishing these transgenic lines, with side-by-side successful controls, it became apparent that generation of constitutively overexpressing CCNF fusion transgenic lines was not feasible. This failure appears to be a result of toxicity associated with persistent overexpression of CCNF fusion proteins in the developing embryo that precludes germ-line transmission of the transgene. The observations from our study indicate that an additional screening stage of zebrafish embryos, and/or the use of a temporal inducible system/mechanism is warranted in studies that aim to develop transgenic models expressing potentially toxic proteins, to circumvent the issues produced by expression during early developmental stages.